WeTrials
Active, not recruiting

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)

What is this study?

This study is testing a personalized cancer vaccine combined with an immunotherapy drug called pembrolizumab. Researchers want to see if this combination is safe and better at preventing high-risk skin melanoma from returning compared to pembrolizumab alone.

Who can participate?

This study is no longer enrolling new participants. It enrolled adults with high-risk melanoma of the skin (stage IIB, IIC, III or IV) that had been completely removed by surgery, who had no signs of the disease left and could start study treatment within 13 weeks of their last surgery. Participants could not have had any earlier whole-body (systemic) treatment for their melanoma, and a sample of their tumor had to be suitable for genetic sequencing. People with melanoma of the eye or of the mucous membranes could not take part.

What will happen?

Participants will receive either the customized cancer vaccine or an inactive placeholder, along with the pembrolizumab immunotherapy drug. Your health will be closely monitored by the medical team throughout the study to check your progress and safety.

Where and when?

The study is running at 165 sites in 26 countries, including 34 in the United States (for example Boston, New York, Philadelphia, Atlanta, Houston, Los Angeles and Seattle) and 7 in Canada (Toronto, Brampton, Montreal, Québec City, Edmonton and Vancouver), with the rest across Europe, Latin America, Asia, Africa and Oceania. It is still active but no longer enrolling new participants. In October 2026, Merck and Moderna reported that adding intismeran autogene to pembrolizumab lowered the risk of the melanoma coming back or death compared with pembrolizumab alone, and the results were presented at the ESMO 2026 Congress. Intismeran autogene is not yet approved.

Key Points
  • 1Tests a personalized cancer vaccine combined with immunotherapy
  • 2Aims to prevent high-risk skin melanoma from coming back after surgery
  • 3Currently active and following existing participants

Related video

Melanoma After Surgery: What the Personalized mRNA Vaccine Trial Really Showed

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Melanoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.